grossman lab banner

Clinical Research Trials

For a list of current clinical trials, click here. 

CONVECTION ENHANCED DELIVERY TRIALS

1. Phase III study to confirm the safety and efficacy diphtheria toxin-conjugated monoclonal antibody to tranferrin receptors in the treatment of malignant gliomas. 2004 to present.

2. Phase III study to confirm the safety and efficacy pseudomonas toxin-conjugated monoclonal antibody to IL-13 receptors in the treatment of malignant gliomas. 2004 to present.

3. Phase II study to confirm the safety and efficacy 131-I labeled monoclonal antibody to histone complex in the treatment of malignant gliomas. 1999 to 2002.

Sponsored by Peregrine Pharmaceuticals to confirm the safety and efficacy of 131I labeled monoclonal antibody to histone complex in the treatment of malignant gliomas. Between 1999 and 2002 the study was conducted at five academic centers in the United States; we enrolled seven patients at our institution.

4. Phase II study to confirm the safety and efficacy diphtheria toxin-conjugated monoclonal antibody to tranferrin receptors in the treatment of malignant gliomas. 1998 to 1999.

Study to confirm the safety and efficacy diphtheria toxin-conjugated monoclonal antibody to tranferrin receptors in the treatment of malignant gliomas. This study closed in 1999 after enrolling nine patients.

RADIATION THERAPY TRIALS

1. Two clinical trials for the treatment of metastatic brain tumors with the Gliasite interstitial radiation delivery device for brachytherapy. 2001 to 2003 and 2004 to present.

Clinical trials for the treatment of metastatic brain tumors with the Gliasite interstitial radiation delivery device for brachytherapy. We enrolled four patients using this novel method of radiation delivery and we are involved in the follow-up study “Gliasite brachytherapy system in the treatment of multiple brain metastasis” and have enrolled two patients.

2. Principal investigator in a multicenter trial of stereotactic radiosurgery versus surgery for single brain metastasis. 1999-2002.